PT  - JOURNAL ARTICLE
AU  - Daniel Herrera-Esposito
AU  - Gustavo de los Campos
TI  - Age-specific rate of severe and critical SARS-CoV-2 infections estimated with multi-country seroprevalence studies
AID  - 10.1101/2021.07.29.21261282
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.29.21261282
4099  - http://medrxiv.org/content/early/2021/10/29/2021.07.29.21261282.short
4100  - http://medrxiv.org/content/early/2021/10/29/2021.07.29.21261282.full
AB  - Knowing the age-specific rates at which individuals infected with SARS-CoV-2 develop severe and critical disease is essential for designing public policy, for epidemic modeling, and for individual risk evaluation. In this study, we present the first estimates of these rates using multi-country serology studies, and data on hospital admissions and mortality from early to mid-2020. We integrated data from those sources using a Bayesian model that accounts for the high heterogeneity between data sources and for the uncertainty associated to the estimates reported from each data source. Our results show that the risk of severe and critical disease increases exponentially with age, but much less steeply than the risk of fatal illness. Importantly, the estimated rate of severe disease outcome in adolescents is between one and two orders of magnitude larger than the reported rate of vaccine side-effects, showing how these estimates are relevant for health policy. Finally, we validate our results by showing that they are in close agreement with the estimates obtained from an indirect method that uses reported infection fatality rates estimates and hospital mortality data.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work did not receive any specific funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is an analysis of publicly available data, already used in previous studies.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and code used in this project are available https://github.com/dherrera1911/estimate_covid_severity.git